MYC/BCL2 DHL has been well studied in the literature and yet no studies have systemically compared the clinicopathologic features of patients who present with de novo disease versus patients with a history of low-grade B-cell lymphoma, mostly FL, and then develop MYC/BCL2 DHL. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.